Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320731170> ?p ?o ?g. }
- W4320731170 endingPage "1194" @default.
- W4320731170 startingPage "1194" @default.
- W4320731170 abstract "Synergistic activity between maintenance temozolomide (TMZm) and individualized multimodal immunotherapy (IMI) during/after first-line treatment has been suggested to improve the overall survival (OS) of adults with IDH1 wild-type MGMT promoter-unmethylated (unmeth) GBM. We expand the data and include the OS of MGMT promoter-methylated (meth) adults with GBM. Unmeth (10 f, 18 m) and meth (12 f, 10 m) patients treated between 27 May 2015 and 1 January 2022 were analyzed retrospectively. There were no differences in age (median: 48 y) or Karnofsky performance index (median: 80). The IMI consisted of 5-day immunogenic cell death (ICD) therapies during TMZm: Newcastle disease virus (NDV) bolus injections and sessions of modulated electrohyperthermia (mEHT); subsequent active specific immunotherapy: dendritic cell (DC) vaccines plus modulatory immunotherapy; and maintenance ICD therapy. There were no differences in the number of vaccines (median: 2), total number of DCs (median: 25.6 × 106), number of NDV injections (median: 31), and number of mEHT sessions (median: 28) between both groups. The median OS of 28 unmeth patients was 22 m (2y-OS: 39%), confirming previous results. OS of 22 meth patients was significantly better (p = 0.0414) with 38 m (2y-OS: 81%). There were no major treatment-related adverse reactions. The addition of IMI during/after standard of care should be prospectively explored." @default.
- W4320731170 created "2023-02-15" @default.
- W4320731170 creator A5004882419 @default.
- W4320731170 creator A5022678830 @default.
- W4320731170 creator A5039085121 @default.
- W4320731170 creator A5049969421 @default.
- W4320731170 creator A5055733751 @default.
- W4320731170 creator A5077396341 @default.
- W4320731170 creator A5089307721 @default.
- W4320731170 date "2023-02-13" @default.
- W4320731170 modified "2023-09-30" @default.
- W4320731170 title "Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience" @default.
- W4320731170 cites W1910257954 @default.
- W4320731170 cites W1910266551 @default.
- W4320731170 cites W1975104842 @default.
- W4320731170 cites W1989291897 @default.
- W4320731170 cites W2032981778 @default.
- W4320731170 cites W2036852706 @default.
- W4320731170 cites W2069711134 @default.
- W4320731170 cites W2081134172 @default.
- W4320731170 cites W2096287682 @default.
- W4320731170 cites W2101781390 @default.
- W4320731170 cites W2111718329 @default.
- W4320731170 cites W2111963329 @default.
- W4320731170 cites W2113090297 @default.
- W4320731170 cites W2115276344 @default.
- W4320731170 cites W2124736921 @default.
- W4320731170 cites W2125372543 @default.
- W4320731170 cites W2135881288 @default.
- W4320731170 cites W2135947790 @default.
- W4320731170 cites W2137605317 @default.
- W4320731170 cites W2143753538 @default.
- W4320731170 cites W2156826863 @default.
- W4320731170 cites W2158681922 @default.
- W4320731170 cites W2165871546 @default.
- W4320731170 cites W2196065821 @default.
- W4320731170 cites W2205491921 @default.
- W4320731170 cites W2261964390 @default.
- W4320731170 cites W2366536035 @default.
- W4320731170 cites W2467863727 @default.
- W4320731170 cites W2487060271 @default.
- W4320731170 cites W2594077503 @default.
- W4320731170 cites W2749747068 @default.
- W4320731170 cites W2765645092 @default.
- W4320731170 cites W2770424503 @default.
- W4320731170 cites W2772664652 @default.
- W4320731170 cites W2778283729 @default.
- W4320731170 cites W2783142536 @default.
- W4320731170 cites W2784096863 @default.
- W4320731170 cites W2788640168 @default.
- W4320731170 cites W2805359783 @default.
- W4320731170 cites W2898283111 @default.
- W4320731170 cites W2902596375 @default.
- W4320731170 cites W2906631024 @default.
- W4320731170 cites W2913046536 @default.
- W4320731170 cites W2913784171 @default.
- W4320731170 cites W2916332433 @default.
- W4320731170 cites W2925307360 @default.
- W4320731170 cites W2932567234 @default.
- W4320731170 cites W2963730372 @default.
- W4320731170 cites W2996066630 @default.
- W4320731170 cites W3006441845 @default.
- W4320731170 cites W3009856270 @default.
- W4320731170 cites W3011642937 @default.
- W4320731170 cites W3011799766 @default.
- W4320731170 cites W3013850623 @default.
- W4320731170 cites W3013929223 @default.
- W4320731170 cites W3034695976 @default.
- W4320731170 cites W3044774318 @default.
- W4320731170 cites W3046857460 @default.
- W4320731170 cites W3047587323 @default.
- W4320731170 cites W3097653525 @default.
- W4320731170 cites W3110054703 @default.
- W4320731170 cites W3113406573 @default.
- W4320731170 cites W3124821786 @default.
- W4320731170 cites W3135350468 @default.
- W4320731170 cites W3158989562 @default.
- W4320731170 cites W3174246647 @default.
- W4320731170 cites W3196916802 @default.
- W4320731170 cites W4207070503 @default.
- W4320731170 cites W4212850243 @default.
- W4320731170 cites W4226120373 @default.
- W4320731170 cites W4226424300 @default.
- W4320731170 cites W4284680403 @default.
- W4320731170 cites W4284885733 @default.
- W4320731170 cites W4285027657 @default.
- W4320731170 cites W4307634601 @default.
- W4320731170 cites W4309183974 @default.
- W4320731170 doi "https://doi.org/10.3390/cancers15041194" @default.
- W4320731170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36831536" @default.
- W4320731170 hasPublicationYear "2023" @default.
- W4320731170 type Work @default.
- W4320731170 citedByCount "2" @default.
- W4320731170 countsByYear W43207311702023 @default.
- W4320731170 crossrefType "journal-article" @default.
- W4320731170 hasAuthorship W4320731170A5004882419 @default.
- W4320731170 hasAuthorship W4320731170A5022678830 @default.
- W4320731170 hasAuthorship W4320731170A5039085121 @default.